LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ironwood reported results of its pivotal Phase III STARS trial of subcutaneous apraglutide on February 29, 2024. Fierce Biotech reported on the same day that, "While the study met its primary endpoint, the results failed to convince investors it can win out over Takeda's Gattex, its potential generic copies and Zealand Pharma's glepaglutide." Based on this news, shares of Ironwood fell y 37.7% in morning trading on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
SOURCE: The Schall Law Firm
View the original
press release on accesswire.com
